Fraile-Ribot, Pablo ArturoZamorano, LauraOrellana, Rocíodel Barrio-Tofiño, EsterSánchez-Diener, IrinaCortés-Lara, SaraLópez-Causapé, CarlaCabot, GabrielBou, GermánMartínez-Martínez, LuisOliver, Antonio2025-11-062025-11-062020-01-27Fraile-Ribot PA, Zamorano L, Orellana R, Del Barrio-Tofiño E, Sánchez-Diener I, Cortes-Lara S, López-Causapé C, Cabot G, Bou G, Martínez-Martínez L, Oliver A; GEMARA-SEIMC/REIPI Pseudomonas Study Group. Activity of imipenem-relebactam against a large collection of pseudomonas aeruginosa clinical isolates and isogenic β-lactam-resistant mutants. Antimicrob Agents Chemother. 2020 Jan 27;64(2):e02165-19.0066-4804https://hdl.handle.net/2183/46306[Abstract] Imipenem and imipenem-relebactam MICs were determined for 1,445 Pseudomonas aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem-relebactam showed the highest susceptibility rate (97.3%), followed by colistin and ceftolozane-tazobactam (both 94.6%). Imipenem-relebactam MICs remained ≤2 μg/ml in all 16 isogenic PAO1 mutants and in 8 pairs of extensively drug-resistant clinical strains that had developed resistance to ceftolozane-tazobactam and ceftazidime-avibactam due to mutations in OXA-10 or AmpC.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Pseudomonas aeruginosaAntibiotic resistanceImipenem-relebactamMultidrug resistanceWhole-genome sequencingβ-lactam resistance mechanismsjournal articleopen access10.1128/aac.02165-19